Ab­b­Vie, Enan­ta post stel­lar hep C PhI­II da­ta, but no one is cheer­ing

First, the good news about new Phase III da­ta from Ab­b­Vie $AB­BV and its part­ner Enan­ta $EN­TA on their hep C com­bo for gle­capre­vir/pi­brentasvir.

The da­ta were ab­solute­ly stel­lar. Ful­ly 99% of geno­type 1, 2, 4, 5 or 6 pa­tients — in 145 of 146 pa­tients — saw their virus dis­ap­pear af­ter 12 weeks of treat­ment. They did that with­out rib­avirin and with­out turn­ing away a like­ly group of re­sis­tant pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER